A Retrospective Observational Study Exploring Factors Influencing the Response to Faricimab in Exudative Age-related Macular Degeneration

A Retrospective Observational Study Exploring Factors Influencing the Response to Faricimab in Exudative Age-related Macular Degeneration - The Effect of Faricimab on Exudative Age-related Macular Degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055171

Enrollment

Registered

2024-08-07

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exudative age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 50 years or older with exudative AMD who received faricimab injections at Kyorin University Hospital between May 2022 and the date of ethical review approval. The subjects will be consecutive cases that have been followed for more than one year.

Exclusion criteria

Exclusion criteria: Patients who refused to participate in this study will be excluded. Additionally, patients who could not obtain OCT and OCTA images at the start of faricimab administration and during treatment, as well as those with other eye diseases, will be excluded.

Design outcomes

Primary

Measure	Time frame
The proportion of responders and non-responders classified by the presence or absence of exudative changes after induction therapy with faricimab and by the dosing intervals at 48 weeks.	—

Secondary

Measure	Time frame
Visual Acuity Changes at 48 Weeks Changes in Optical Coherence Tomography (OCT) and Optical Coherence Tomography Angiography (OCTA)	—

Countries

Japan

Contacts

Public ContactKeiko Kataoka

Kyorin Univerisyt Department of Ophthalmology

keiko-kataoka@ks.kyorin-u.ac.jp0422-47-5511

Outcome results